Allschwil, Switzerland – April 6, 2023
Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2022, will be held on Thursday, May 4, 2023, at 09.00 CEST at the Congress Center, Messe Basel, Switzerland.
Mathieu Simon, Chairman of the Board of Idorsia commented:
“Alongside the regular business of approving the accounts and reporting for 2022, this year we propose several changes to the company’s Articles of Association, to bring Idorsia in-line with Swiss corporate law reform which entered into force this year. In addition, I’m pleased to say all Board members will stand for re-election and we are proposing an additional member to the Board. Dr Sophie Kornowski is an industry veteran, who has been working for large and medium-sized pharmaceutical corporations and has an impeccable track-record ranging from commercial expertise to business development aspects. In addition, her recent experience with private equity and venture capital will bring an additional skill set to the current board.”
Notes to Shareholders
The invitation was published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) today and will be distributed to Shareholders by post. It is also available, together with the Company’s Annual Report and Compensation Report, on www.idorsia.com/agm.
In order to attend and vote at the AGM, shareholders must be registered in the company's shareholder register by April 25, 2023, 17:00 CEST, at the latest.
Notes to the editor
Agenda for the AGM 2023
1. Annual Report 2022, Consolidated Financial Statements 2022, Statutory Financial Statements 2022, and Compensation Report 2022
1.1 Approval of Annual Report 2022, Consolidated Financial Statements 2022, and Statutory Financial Statements 2022
1.2 Consultative vote on the Compensation Report 2022
2. Appropriation of available earnings
3. Discharge of the Board of Directors and of the Executive Committee
4. Board and Nominating, Governance & Compensation Committee elections
4.1 (Re-)election of members of the Board of Directors
4.2 Re-election of the Chair of the Board of Directors
4.3 (Re-)election of members of the Nominating, Governance & Compensation Committee
5. Approval of Board compensation and Executive Committee compensation
5.1 Approval of Board compensation (Non-Executive Directors) for the
2023–2024 term of office
5.2 Approval of Executive Committee compensation for 2024
6. Re-election of the Independent Proxy
7. Re-election of the statutory auditors
8. Amendments to the Articles of Association
8.1 Purpose of the Company
8.2 Conditional Capital
8.3 Capital Range
8.4 Shares
8.5 Shareholder Matters
8.6 Corporate Governance
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,300 highly qualified specialists dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Attachment
